Cidara Therapeutics Stock Analysis

Cidara Stock Analysis Notes

About 30.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 5.2. Cidara Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 24th of April 2024. Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Cidara Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Cidara Therapeutics please contact Jeffrey Stein at 858 752 6170 or go to https://www.cidara.com.

Cidara Therapeutics Investment Alerts

Cidara Therapeutics Upcoming and Recent Events

Cidara Largest EPS Surprises

View All Earnings Estimates

Cidara Stock Institutional Investors

Note, although Cidara Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cidara Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.49 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cidara Therapeutics's market, we take the total number of its shares issued and multiply it by Cidara Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Cidara Profitablity

The company has Profit Margin (PM) of (0.36) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.35.

Management Efficiency

Cidara Therapeutics has return on total asset (ROA) of (0.2672) % which means that it has lost $0.2672 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.5892) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cidara Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 2.93 in 2024, whereas Return On Tangible Assets are likely to drop (0.36) in 2024. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 6.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 810.8 K in 2024.

Technical Drivers

As of the 25th of April, Cidara Therapeutics shows the risk adjusted performance of (0.03), and Mean Deviation of 3.82. Cidara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Cidara Therapeutics, which can be compared to its peers. Please confirm Cidara Therapeutics market risk adjusted performance and treynor ratio to decide if Cidara Therapeutics is priced correctly, providing market reflects its regular price of 12.29 per share. Given that Cidara Therapeutics has information ratio of (0.08), we suggest you to validate Cidara Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Cidara Therapeutics Price Movement Analysis

Cidara Therapeutics Insider Trading Activities

Cidara Therapeutics Predictive Daily Indicators

Cidara Therapeutics Forecast Models

Cidara Therapeutics' time-series forecasting models are one of many Cidara Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cidara Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cidara Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cidara shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cidara Therapeutics. By using and applying Cidara Stock analysis, traders can create a robust methodology for identifying Cidara entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cidara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cidara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cidara Therapeutics stock analysis indicators help investors evaluate how Cidara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cidara Therapeutics shares will generate the highest return on investment. By understating and applying Cidara Therapeutics stock analysis, traders can identify Cidara Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Cidara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. If investors know Cidara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cidara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cidara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cidara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cidara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.